Varicella-zoster virus as a live recombinant vaccine
US5310668A · kind A · utility
68Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 1992 |
| Grant date | May 10, 1994 |
| Priority date | — |
| Expiry date | Feb 27, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2730/10122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.